AusIndustry Awards Recce Support for AU$5.6 Million of Technically Advanced Overseas Drug Development


Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, have announced that it has been awarded an Advanced Finding upon AU$5.6 million of overseas drug development from AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science.


The substantial 43.5% rebate applicable to Australian Research and Development, is now awarded to Recce to include its overseas advanced drug development for the fi nancial year ending June 2017 and through the following two fi nancial years to mid-2019.


The funds include and cover some expenditure already undertaken and apply to all antibiotics under development according to: pilot plant and development testing; toxicology studies; effi cacy studies; pharmacology studies; analytical methods.


The reassurance of the Australian Government’s commitment to reimburse Recce for its local and now international drug development activities, works to reinforce the Company’s focus on the United States as a major component of the world pharmaceutical market. The reimbursement of developmental funds will greatly support Recce’s present FDA activities and anticipated human clinical trials.


Dr Graham Melrose, Recce’s Executive Chairman, said: “The Australian life sciences sector is booming. With companies listed on the ASX combined market capitalisation of more than AU$80 billion, it continues to be a signifi cant economic driver for our country. We thank the Australian Government for awards such as this, which encourage innovation and development within the sector.”


44893pr@reply-direct.com


Sino-German Strategic Cooperation Creates a new Chapter for Pfeiffer Vacuum in China


Pfeiffer Vacuum has signed a strategic cooperation agreement with Lanzhou Institute of Physics (LIP) in Asslar, Germany. As one of the founders of the Chinese Vacuum Society, the Lanzhou Institute of Physics is a pioneer in vacuum technology in China. LIP is also one of the fi rst institutes in China which has been directly engaged in satellite and spacecraft development and is therefore a part of the China Academy of Space Technology (CAST) since 1968. Pfeiffer Vacuum and LIP will cooperate in research and development to create vacuum solutions for aerospace applications, vacuum metrology, vacuum calibration and other applications.


The strong cooperation between the two companies is in line with the common interests of both sides. Pfeiffer Vacuum is contributing with its extensive line of solutions, products and services ranging from vacuum pumps, measurement and analysis equipment to complex vacuum systems and its global sales and


service network, while LIP is introducing its leading position in the China vacuum industry.


On 17 October 2017, the LIP-Pfeiffer Vacuum Joint Center for Vacuum Technology was established in Lanzhou, Gansu province. The centre will provide a platform for future projects and joint developments. As mentioned by LIP during the opening ceremony, it will connect ‘Made in China 2025’ and the German ‘Industry 4.0’ initiatives.


The start of the cooperation between Pfeiffer Vacuum and the Lanzhou Institute of Physics is in conjunction with the 10th anniversary of Pfeiffer Vacuum in China. “We hope that with our experience and advanced technology we can provide leading vacuum solutions and fi rst-class service to create a bright future for our Chinese customers,” said Vic Chen, General Manager of Pfeiffer Vacuum (Shanghai) Co, Ltd.


The LIP-Pfeiffer Vacuum Joint Center for Vacuum Technology unveiling ceremony in Lanzhou, Gansu Province, China.


44643pr@reply-direct.com


UK/Chinese Collaboration to Develop Innovative Technologies for Epigenetic Analysis Announced


Porvair Sciences are teaming up with Suzhou Tianlong Bio Technology Co Ltd, together with Swansea University and Xi’an Jiaotong University in a collaborative project entitled, ‘Automating & Stratifi cation of Epigenetics in Healthcare’ that is part of the Innovate UK/ Jiangsu Industrial Challenge Programme.


The project will integrate Porvair’s innovative solid-state chromatin immunoprecipitation platform, Chromatrap® with Tianlong’s expertise in automated robotic technologies and diagnostic multiplex PCR kits to develop innovative technologies in epigenetic characterisation for patient stratifi cation in renowned precision


medicine. Academics in cancer epigenetics from Swansea University and Xi’an Jiaotong University will support the project by providing insights and direction for the application in cancer research and drug development.


Dr Amy Beynon, Technical and Business


Development Manager at Porvair Sciences said: “Developing new technologies to simplify and advance epigenetics research is the driving force here at Porvair. Combining Chromatrap with Tianlong’s expertise in diagnostic multiplex arrays, we will provide a streamlined workfl ow across both research and clinical applications. The ultimate collaborative goal is to provide


innovative tools that improve diagnostic options for patients and informed novel stratifi ed therapeutics.”


The project will provide an excellent opportunity for Porvair Sciences and Tianlong to develop an automated ChIP assay that enables users to perform chromatin isolation straight through to multiplex PCR, completely hands-free. Researchers and diagnostic laboratories will be able to simultaneously analyse multiple epigenetic


marks using less material and


obtain better quantitative analyses. Diagnostic multiplex arrays are currently available for a number of cancer disease states, but application


Clover Biopharmaceuticals Selects GE’s Biomanufacturing Platform for New Production Facility in China


Clover Biopharmaceuticals has chosen GE Healthcare’s FlexFactory, a biomanufacturing platform based on single-use technologies, for its new facility located in Changxing, Zhejiang in China. The new facility will mainly be used to produce biological fusion protein products, including innovative drugs and biosimilars. This will help Clover Biopharmaceuticals to bring local access to biologic therapies faster, while also opening global markets through the proven track record of FlexFactory in meeting global regulatory requirements and quality standards. The biomanufacturing facility includes two 2,000-litre bioreactors from GE, and it will be operational in the latter half of 2018.


Clover Biopharmaceuticals’ new production facility will be located in one of the national economic development zones in China, Changxing Economic and Technological Development Zone, where a new biopharmaceutical industrial cluster is being developed. China has a broader strategy on biotechnological innovation per the government’s 13th Five-Year Plan, and there are plans to build up to twenty science parks for biomedicine by 2020 to accelerate local research and development activities. In 2015, the Chinese biopharmaceutical market was valued approximately at US$13 billion, and the


estimated annual growth rate (CAGR) is around 13% for the next few years.


“Adopting high-quality technologies and driving innovation in our manufacturing operations is important for Clover Biopharmaceuticals. GE’s FlexFactory represents the latest in biomanufacturing technologies, and it will help us establish fl exible production capacity quickly, while fulfi lling good manufacturing practices (GMP) requirements,” said Dr Peng Liang, Co-founder, Chairman and President of Clover Biopharmaceuticals.


“China has one of the fastest growing biopharmaceutical industries in the world, and it is important when new production facilities are being built that the chosen biomanufacturing technologies support this positive development, bringing high-quality biologics fast to market. We are excited to collaborate with Clover Biopharmaceuticals and to contribute to their promising and ambitious product pipeline by delivering a fl exible, start-to-fi nish biomanufacturing platform based on single-use technologies,” said Sven Henrichwark, General Manager, Global Commercial BioProcess, GE Healthcare Life Sciences.


44923@reply-direct.com Dr Peng Liang


in breast and ovarian cancers is non-existent which greatly impacts the development of novel therapeutics.


Dr Lindsay Parkes a Senior Research Scientist at Porvair Sciences emphasised that “the opportunity to be the fi rst to provide fundamental technologies for precision medicine, starting with breast and ovarian cancer, we can begin to shed light on the underlying epigenetics processes in cancer biology and take the fi rst steps in developing therapeutics solutions for patients.”


44663pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52